Stockreport

Clovis down 3% premarket as Leerink cuts view [Seeking Alpha]

Clovis Oncology, Inc.  (CLVS) 
Last clovis oncology, inc. earnings: 2/24 04:05 pm Check Earnings Report
PDF Clovis Oncology (NASDAQ:CLVS3%PROfoundLeerink believes Lynparza will significantly limit the opportunity for Clovis' PARP inhibitor Rubraca (rucaparib) in prostate cance [Read more]